SKYTROFA® (Lonapegsomatropin-tcgd), The First Therapy Discovered for Pediatric Growth Hormone Deficiency
Acendis Pharma has made a significant discovery in the form of SKYTROFA (lonapegsomatropin-tcgd), a groundbreaking treatment for pediatric growth hormone deficiency.
This once-weekly therapy is specifically designed for patients aged one year and older, weighing at least 11.5kg, who experience limited growth due to insufficient secretion of endogenous Growth Hormone (GH).
SKYTROFA® (lonapegsomatropin-tcgd) functions as a prodrug, delivering somatropin gradually over a one-week period. It comes in single-use, prefilled cartridges, available in nine different dosage strengths, providing convenient flexibility in dosing.
It is important to note that SKYTROFA should not be administered to patients with acute critical illness following open heart surgery, abdominal surgery, or multiple accidental trauma. Additionally, there is an increased risk of malignancy progression in patients with active malignancies when treated with somatropin. Furthermore, higher doses of SKYTROFA may lead to decreased insulin sensitivity.
Notably, SKYTROFA stands as the sole FDA-approved weekly once treatment commercially available in the United States for the treatment of growth hormone deficiency.
